BLEOMYCIN SULFATE Drug Patent Profile
✉ Email this page to a colleague
When do Bleomycin Sulfate patents expire, and what generic alternatives are available?
Bleomycin Sulfate is a drug marketed by Cipla, Fresenius Kabi Usa, Hikma, Hospira, Meitheal, Pharmachemie Bv, Teva Parenteral, and Teva Pharms Usa. and is included in eight NDAs.
The generic ingredient in BLEOMYCIN SULFATE is bleomycin sulfate. There are six drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the bleomycin sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Bleomycin Sulfate
A generic version of BLEOMYCIN SULFATE was approved as bleomycin sulfate by HOSPIRA on March 10th, 2000.
Summary for BLEOMYCIN SULFATE
US Patents: | 0 |
Applicants: | 8 |
NDAs: | 8 |
Finished Product Suppliers / Packagers: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 55 |
Clinical Trials: | 79 |
Patent Applications: | 4,004 |
Formulation / Manufacturing: | see details |
DailyMed Link: | BLEOMYCIN SULFATE at DailyMed |
Recent Clinical Trials for BLEOMYCIN SULFATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Jinnah Postgraduate Medical Centre | Phase 2 |
AIDS Malignancy Consortium | Phase 1 |
The EMMES Corporation | Phase 1 |
Pharmacology for BLEOMYCIN SULFATE
Drug Class | Cytoprotective Agent |